



IN THE CLAIMS

Please amend the claims as follows:

1. (Original) A peptide derived from the amino acid sequence of human WT1 set forth in SEQ ID NO: 1 and having activity as an HLA-A26-binding cancer antigen peptide.
- 2.(Original) The peptide according to claim 1, which comprises an amino acid sequence set forth in SEQ ID NO: 2 (Asp Gln Leu Lys Arg His Gln Arg Arg), SEQ ID NO: 8 (Val Thr Phe Asp Gly Thr Pro Ser Tyr), or SEQ ID NO: 9 (Gln Gly Ser Leu Gly Glu Gln Gln Tyr).
3. (Currently amended) The peptide according to claim 1 ~~or~~ 2, which is an epitope peptide.
4. (Currently amended) A polynucleotide encoding a peptide described in ~~any one of~~ claim[[s]] 1 ~~to~~ 3.
5. (Original) An expression vector containing the polynucleotide described in claim 4.
6. (Original) A cell containing the expression vector described in claim 5.
7. (Currently amended) A process for producing a peptide described in ~~any one of~~ claim[[s]] 1 ~~to~~ 3, which comprises culturing the a cell described in claim 6 comprising an expression vector comprising a polynucleotide encoding a peptide derived from the amino acid sequence of human WT1 set forth in SEQ ID NO:1 under ~~the~~ conditions where the peptide can be expressed.

8. (Currently amended) An antibody which specifically binds to the peptide described in claim 1 ~~or~~ 2.

9.(Currently amended) An antigen-presenting cell on which a complex between an HLA-A26-binding cancer antigen peptide derived from the amino acid sequence of human WT1 set forth in SEQ ID NO: 1, ~~preferably a peptide described in claim 2~~ and an HLA-A26 antigen is presented.

10. (Currently amended) A CTL which recognizes a complex between an HLA-A26-binding cancer antigen peptide derived from the amino acid sequence of human WT1 set forth in SEQ ID NO: 1, ~~preferably a peptide described in claim 2~~ and an HLA-A26 antigen.

11.(Currently amended) A pharmaceutical composition which comprises a peptide described in ~~any one of claim~~[[s]] 1 to 3, ~~an expression vector described in claim 5, a cell described in claim 6, an antigen presenting cell described in claim 9, or a CTL described in claim 10,~~ together with a pharmaceutically acceptable carrier.

12. (Original) The pharmaceutical composition according to claim 11, which is used as a CTL inducer.

13. (Original) The pharmaceutical composition according to claim 11, which is used as cancer vaccine.

14. (Currently amended) An HLA monomer, dimer, tetramer or pentamer comprising an HLA-A26-binding cancer antigen peptide derived from the amino acid sequence of human

WT1 set forth in SEQ ID NO: 1, ~~preferably a peptide described in claim 2~~, together with an HLA-A26 antigen.

15.(Original) A reagent for the detection of CTLs specific for an HLA-A26-binding cancer antigen peptide derived from WT1, which reagent comprises an HLA monomer, dimer, tetramer or pentamer described in claim 14 as an ingredient.

16. (Original) A pharmaceutical composition which comprises any one of the following a) to f) together with a pharmaceutically acceptable carrier:

- a) a peptide comprising the amino acid sequence set forth in SEQ ID NO: 3 (Asp Leu Asn Ala Leu Leu Pro Ala Val),
- b) an epitope peptide comprising the peptide of a) above,
- c) an expression vector containing a polynucleotide encoding the peptide of a) or b) above,
- d) a cell containing the expression vector of c) above,
- e) an antigen-presenting cell on which a complex between the peptide of a) above and an HLA-A*0201 antigen is presented, and
- f) a CTL which recognizes the complex between the peptide of a) and an HLA-A*0201 antigen.

17. (Original) The pharmaceutical composition according to claim 16, which is used as a CTL inducer.

18.(Original) The pharmaceutical composition according to claim 16, which is used as cancer vaccine.

19.(Original) An HLA monomer, dimer, tetramer or pentamer which comprises a peptide comprising the amino acid sequence set forth in SEQ ID NO: 3 (Asp Leu Asn Ala Leu Leu Pro Ala Val) together with an HLA-A* 0201 antigen.

20. (Original) A reagent for the detection of CTLs specific for HLA-A* 0201-binding cancer antigen peptide derived from WT1, which reagent comprises an HLA monomer, dimer, tetramer or pentamer described in claim 19 as an ingredient.